ImmunoGen Reports Pipeline Progress and 2017 Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Caribou Biosciences to halt CAR-T programs, explore sale
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- Francis Halzen wins Nobel physics prize for Antarctic 'ghost particle' hunt
Immunogen (IMGN) Tops Q4 EPS by 1c
February 9, 2018 6:32 AM ESTImmunogen (NASDAQ: IMGN) reported Q4 EPS of ($0.11), $0.01 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $39.45 million versus the consensus estimate of $32.71 million.
Financial Guidance
For 2018, ImmunoGen expects:
revenues between $60 million and $65 million;operating expenses between $185 million and $190... More


